Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Liver Cancer
Interventions: bevacizumab, dexamethasone, floxuridine, protein expression analysis, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging; Biological · Drug · Genetic + 2 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2024
U.S. locations: 2
States / cities: New York, New York

Conditions: Cardiovascular Health, Cardiovascular Risk Factor
Interventions: Potassium chloride supplement, Placebo; Dietary Supplement
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Cancer
Interventions: IMC-1121B, 1121B; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Indianapolis, Indiana • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Vascular Formation
Interventions: Exercise; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Childhood Obesity, Inflammation
Interventions: Moderate exercise, High Intensity Interval Exercise; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 13 Years to 17 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Renal Insufficiency, Chronic
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Aurora, Colorado • Nashville, Tennessee

Conditions: Overweight and Obesity, Insulin Resistance
Interventions: Placebo - Cap, Amiloride Pill; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 30 Years to 70 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Healthy
Interventions: Active breakfast, Control breakfast; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 55 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Aging
Interventions: L-Citrulline, capsule; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Fuchs Endothelial Corneal Dystrophy
Interventions: STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID, Placebo (Vehicle) BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 8 more

Conditions: Cardiovascular Diseases
Interventions: Brachial artery ultrasound imaging; Procedure
Lead sponsor: Everist Genomics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Derby, Connecticut • Milwaukee, Wisconsin

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Interventions: AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 42
States / cities: Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more

Conditions: Endothelial Dysfunction
Interventions: darapladib, placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Peripheral Arterial Disease, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 22 Years to 89 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Aging, Oxidative Stress, Vascular Endothelium, Skeletal Muscle, Antioxidants
Interventions: MITO-AO, PB-125, Placebo, Passive Leg Movement (PLM), Plantar flexion, Isometric knee extensor test, Bed rest; Dietary Supplement · Other
Lead sponsor: Joel Trinity; Other
Eligibility: 65 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Kidney Disease
Interventions: Pioglitazone, Placebo, Nitroglycerin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obstructive Sleep Apnea of Adult
Interventions: Atorvastatin 10mg, Placebo, Continuous Positive Airway Pressure Therapy; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Adverse Childhood Experiences, Vascular Dilatation, Sleep, Sleep Disturbance, Psychosocial Stressor, Psychological Trauma, Endothelial Dysfunction, Inflammation, Oxidative Stress
Interventions: Cognitive Behavioral Therapy for Insomnia (CBT-i); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 29 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Healthy
Interventions: Dietary Sodium Restriction, Control; Other
Lead sponsor: University of Delaware; Other
Eligibility: 21 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Heart Failure With Reduced Ejection Fraction
Interventions: TVS, SHAM; Device
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Acute ST Elevation Myocardial Infarction
Interventions: Epoetin alfa; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 21 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 16
States / cities: Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 11 more

Conditions: Systemic Sclerosis, Pulmonary Hypertension, Scleroderma
Interventions: No intervention given; Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Cataract
Interventions: DisCoVisc®, Healon, Amvisc Plus; Device · Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 49 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: HIV, Cardiovascular Diseases, Atherosclerosis
Interventions: Pentoxifylline, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

The Potassium Supplementation Study

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

Effect of Regular Exercise on Vascular Function and Cardiovascular Risk in a Sedentary Work Force

CASH- Children Active to Stay Healthy

Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)

ENAC Blockade and Arterial Stiffness

Acute Berry Intake on Metabolic Control and Cognitive Function

L-Citrulline and Endothelial Function

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

Brachial Artery Ultrasound Imaging: A Repeatability Study

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Progenitor Cells and Coronary Atherosclerosis in Humans

Endothelial Function and Vein Graft Remodeling

Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

Vascular Endothelial Dysfunction in Sleep Apnea

The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies

Vascular Effects of Dietary Salt in Humans With Salt-Resistant Blood Pressure

Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension

To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.

Evaluating the Effectiveness of Pentoxifylline at Improving Blood Vessel Function in HIV-infected People Not Receiving Antiretroviral Medications